These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35370887)

  • 1. Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies.
    Nakamura K; Mokliatchouk O; Arnold DL; Yousry TA; Kappos L; Richert N; Ayling-Rouse K; Miller C; Fisher E
    Front Neurol; 2022; 13():809273. PubMed ID: 35370887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
    Gold R; Giovannoni G; Phillips JT; Fox RJ; Zhang A; Marantz JL
    Neurol Ther; 2016 Jun; 5(1):45-57. PubMed ID: 26932146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies.
    Amezcua L; Mao-Draayer Y; Vargas WS; Farber R; Schaefer S; Branco F; England SM; Belviso N; Lewin JB; Mendoza JP; Shankar SL;
    Neurol Ther; 2023 Jun; 12(3):883-897. PubMed ID: 37061656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE.
    Gold R; Arnold DL; Bar-Or A; Fox RJ; Kappos L; Chen C; Parks B; Miller C
    Ther Adv Neurol Disord; 2020; 13():1756286420915005. PubMed ID: 32426039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
    Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
    Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
    Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
    Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
    Gold R; Arnold DL; Bar-Or A; Hutchinson M; Kappos L; Havrdova E; MacManus DG; Yousry TA; Pozzilli C; Selmaj K; Sweetser MT; Zhang R; Yang M; Potts J; Novas M; Miller DH; Kurukulasuriya NC; Fox RJ; Phillips TJ
    Mult Scler; 2017 Feb; 23(2):253-265. PubMed ID: 27207449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM.
    Fox RJ; Gold R; Phillips JT; Okwuokenye M; Zhang A; Marantz JL
    Neurol Ther; 2017 Dec; 6(2):175-187. PubMed ID: 28770420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
    Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
    Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S; Kumar J; Arndorfer S; Zhu X; Zivkovic M; Tencer T
    CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
    Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
    Kappos L; Giovannoni G; Gold R; Phillips JT; Arnold DL; Hotermans C; Zhang A; Viglietta V; Fox RJ;
    Eur J Neurol; 2015 Apr; 22(4):664-71. PubMed ID: 25557371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
    Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
    Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
    Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 2-stage model of heterogenous treatment effects for brain atrophy in multiple sclerosis utilizing the MS PATHS research network.
    Hersh CM; Sun Z; Conway DS; Sotirchos ES; Fitzgerald KC; Hua LH; Ziemssen T; Naismith RT; Pellegrini F; Grossman C; Campbell N
    Mult Scler Relat Disord; 2024 Nov; 91():105847. PubMed ID: 39260226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
    Gopal S; Mikulskis A; Gold R; Fox RJ; Dawson KT; Amaravadi L
    Mult Scler; 2017 Dec; 23(14):1875-1883. PubMed ID: 28156185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.
    Viglietta V; Miller D; Bar-Or A; Phillips JT; Arnold DL; Selmaj K; Kita M; Hutchinson M; Yang M; Zhang R; Dawson KT; Sheikh SI; Fox RJ; Gold R
    Ann Clin Transl Neurol; 2015 Feb; 2(2):103-18. PubMed ID: 25750916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.